James P. Allison, PhD

James P. Allison, PhD, is Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center in Houston. In 2018, Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine, with Tasuku Honjo, MD, PhD, for launching an effective new way to attack cancer by treating the immune system rather than the tumor.

Dr. Allison’s work led to the development of the first immune checkpoint inhibitor—ipilimumab, which was approved by the U.S. Food and Drug Administration in 2011 for treatment of late-stage melanoma. ■